What is Karyopharm Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-05-20), Karyopharm Therapeutics's share price is €1.048.
Karyopharm Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.95. Hence, Karyopharm Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Karyopharm Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Karyopharm Therapeutics's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was €-0.35.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.95.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 28.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 20.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.60% per year.
During the past 13 years, Karyopharm Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 28.50% per year. The lowest was -23.70% per year. And the median was -0.55% per year.
Karyopharm Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Karyopharm Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Price-to-Operating-Cash-Flow Chart
|
Karyopharm Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Karyopharm Therapeutics Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Karyopharm Therapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Karyopharm Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Price-to-Operating-Cash-Flow falls into.
Karyopharm Therapeutics Price-to-Operating-Cash-Flow Calculation
Karyopharm Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.048 | / | -0.946 |
| = | |
Karyopharm Therapeutics's Share Price of today is €1.048.
Karyopharm Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.95.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Karyopharm Therapeutics (STU:25K) Business Description
Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Karyopharm Therapeutics (STU:25K) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:25K has been successfully added to your